BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-69. [DOI: 10.1002/hep.23046] [Cited by in Crossref: 318] [Cited by in F6Publishing: 286] [Article Influence: 26.5] [Reference Citation Analysis]
Number Citing Articles
1 Hassan W, Ding L, Gao RY, Liu J, Shang J. Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders. Cytokine 2014;66:133-42. [PMID: 24491813 DOI: 10.1016/j.cyto.2013.12.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
2 Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology. 2013;57:81-92. [PMID: 22508243 DOI: 10.1002/hep.25789] [Cited by in Crossref: 159] [Cited by in F6Publishing: 145] [Article Influence: 19.9] [Reference Citation Analysis]
3 Michalczuk MT, Kappel CR, Birkhan O, Bragança AC, Alvares-da-Silva MR. HOMA-AD in Assessing Insulin Resistance in Lean Noncirrhotic HCV Outpatients. Int J Hepatol 2012;2012:576584. [PMID: 22848841 DOI: 10.1155/2012/576584] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, Hamza S, Corradini SG, Burza MA, Guyot E, Donati B, Spengler U, Hillon P, Toniutto P, Henrion J, Franchimont D, Devière J, Mathurin P, Moreno C, Romeo S, Deltenre P. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology 2014;59:2170-7. [PMID: 24114809 DOI: 10.1002/hep.26767] [Cited by in Crossref: 145] [Cited by in F6Publishing: 131] [Article Influence: 20.7] [Reference Citation Analysis]
5 Sharma K, Zajc I, Žiberna L. Dietary vitamin D equilibrium in serum ameliorates direct bilirubin associated diabetes mellitus. Chem Biol Interact 2021;337:109399. [PMID: 33503443 DOI: 10.1016/j.cbi.2021.109399] [Reference Citation Analysis]
6 Vanni E, Bugianesi E. Obesity and Liver Cancer. Clinics in Liver Disease 2014;18:191-203. [DOI: 10.1016/j.cld.2013.09.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
7 Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys. 2014;548:20-37. [PMID: 24631571 DOI: 10.1016/j.abb.2014.02.015] [Cited by in Crossref: 121] [Cited by in F6Publishing: 99] [Article Influence: 17.3] [Reference Citation Analysis]
8 Mera K, Uto H, Mawatari S, Ido A, Yoshimine Y, Nosaki T, Oda K, Tabu K, Kumagai K, Tamai T, Moriuchi A, Oketani M, Shimada Y, Hidaka M, Eguchi S, Tsubouchi H. Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C. BMC Gastroenterol 2014;14:27. [PMID: 24524410 DOI: 10.1186/1471-230X-14-27] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
9 Hong Y, Choi SI, Hong E, Kim GH. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice. J Food Sci 2020;85:2216-26. [PMID: 32579753 DOI: 10.1111/1750-3841.15166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology. 2016;150:1835-1848. [PMID: 26971824 DOI: 10.1053/j.gastro.2016.03.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 10.2] [Reference Citation Analysis]
11 Xu J, Lai KKY, Verlinsky A, Lugea A, French SW, Cooper MP, Ji C, Tsukamoto H. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol. 2011;55:673-682. [PMID: 21256905 DOI: 10.1016/j.jhep.2010.12.034] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 9.4] [Reference Citation Analysis]
12 Chang ML, Hsu CM, Tseng JH, Tsou YK, Chen SC, Shiau SS, Yeh CT, Chiu CT. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J Gastroenterol Hepatol. 2015;30:329-336. [PMID: 25091195 DOI: 10.1111/jgh.12705] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
13 Arrese M, Karpen SJ. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther 2010;87:473-8. [PMID: 20200515 DOI: 10.1038/clpt.2010.2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
14 Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Groszmann RJ;  Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555-561. [PMID: 21567436 DOI: 10.1002/hep.24418] [Cited by in Crossref: 155] [Cited by in F6Publishing: 126] [Article Influence: 15.5] [Reference Citation Analysis]
15 Semaan A, Dietrich D, Bergheim D, Dietrich J, Kalff JC, Branchi V, Matthaei H, Kristiansen G, Fischer HP, Goltz D. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. Virchows Arch. 2017;470:185-196. [PMID: 27913861 DOI: 10.1007/s00428-016-2051-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
16 Ehtesham NZ, Nasiruddin M, Alvi A, Kumar BK, Ahmed N, Peri S, Murthy KJ, Hasnain SE. Treatment end point determinants for pulmonary tuberculosis: human resistin as a surrogate biomarker. Tuberculosis (Edinb) 2011;91:293-9. [PMID: 21606003 DOI: 10.1016/j.tube.2011.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
17 Gaudio E, Nobili V, Franchitto A, Onori P, Carpino G. Nonalcoholic fatty liver disease and atherosclerosis. Intern Emerg Med. 2012;7 Suppl 3:S297-S305. [PMID: 23073871 DOI: 10.1007/s11739-012-0826-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
18 Kukla M. Angiogenesis: a phenomenon which aggravates chronic liver disease progression. Hepatol Int. 2013;7:4-12. [PMID: 26201617 DOI: 10.1007/s12072-012-9391-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
19 Carr RM, Correnti J. Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci. 2015;1353:1-20. [PMID: 25998863 DOI: 10.1111/nyas.12787] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
20 Jiménez-Castro MB, Casillas-Ramírez A, Negrete-Sánchez E, Avalos-de León CG, Gracia-Sancho J, Peralta C. Adipocytokines in Steatotic Liver Surgery/Transplantation. Transplantation 2019;103:71-7. [PMID: 30586349 DOI: 10.1097/TP.0000000000002098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis 2011;29:202-10. [PMID: 21734385 DOI: 10.1159/000323886] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
22 Fisher L, Srikusalanukul W, Fisher A, Smith P. Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes. Int J Med Sci 2015;12:100-15. [PMID: 25589886 DOI: 10.7150/ijms.10696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
23 Oyama LM, do Nascimento CM, Carnier J, de Piano A, Tock L, Sanches Pde L, Gomes FA, Tufik S, de Mello MT, Dâmaso AR. The role of anorexigenic and orexigenic neuropeptides and peripheral signals on quartiles of weight loss in obese adolescents. Neuropeptides 2010;44:467-74. [PMID: 20709393 DOI: 10.1016/j.npep.2010.07.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
24 Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol. 2013;19:6947-6956. [PMID: 24222938 DOI: 10.3748/wjg.v19.i41.6947] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
25 Friedman SL. Hepatic Fibrosis. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 295-315. [DOI: 10.1002/9781119950509.ch12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Weinstein G, Davis-Plourde K, Himali JJ, Zelber-Sagi S, Beiser AS, Seshadri S. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. Liver Int 2019;39:1713-21. [PMID: 31155826 DOI: 10.1111/liv.14161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
27 Carpino G, Renzi A, Onori P, Gaudio E. Role of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks. Int J Mol Sci. 2013;14:20112-20130. [PMID: 24113587 DOI: 10.3390/ijms141020112] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
28 Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol. 2010;16:1943-1952. [PMID: 20419831 DOI: 10.3748/wjg.v16.i16.1943] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
29 Britton L, Jaskowski LA, Bridle K, Secondes E, Wallace D, Santrampurwala N, Reiling J, Miller G, Mangiafico S, Andrikopoulos S, Subramaniam VN, Crawford D. Ferroportin Expression in Adipocytes Does Not Contribute to Iron Homeostasis or Metabolic Responses to a High Calorie Diet. Cell Mol Gastroenterol Hepatol 2018;5:319-31. [PMID: 29552621 DOI: 10.1016/j.jcmgh.2018.01.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
30 Ha NB, Cho SJ, Mohamad Y, Kent D, Jun G, Wong R, Swarnakar V, Lin S, Maher JJ, Lai JC. Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis. Dig Dis Sci 2021. [PMID: 34136974 DOI: 10.1007/s10620-021-07099-8] [Reference Citation Analysis]
31 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ishtiaq SM, Rashid H, Hussain Z, Arshad MI, Khan JA. Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease. Rev Endocr Metab Disord. 2019;20:253-261. [PMID: 31656991 DOI: 10.1007/s11154-019-09510-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
33 Kramer AS, Latham B, Diepeveen LA, Mou L, Laurent GJ, Elsegood C, Ochoa-Callejero L, Yeoh GC. InForm software: a semi-automated research tool to identify presumptive human hepatic progenitor cells, and other histological features of pathological significance. Sci Rep 2018;8:3418. [PMID: 29467378 DOI: 10.1038/s41598-018-21757-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
34 Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221-239. [PMID: 25045276 DOI: 10.2147/ceg.s62831] [Cited by in Crossref: 53] [Cited by in F6Publishing: 110] [Article Influence: 7.6] [Reference Citation Analysis]
35 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 64-85. [DOI: 10.1016/b978-1-4377-0881-3.00005-x] [Cited by in Crossref: 8] [Article Influence: 0.9] [Reference Citation Analysis]
36 Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365-383. [PMID: 20415685 DOI: 10.1111/j.1463-1326.2009.01176.x] [Cited by in Crossref: 142] [Cited by in F6Publishing: 134] [Article Influence: 14.2] [Reference Citation Analysis]
37 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
38 Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology 2011;55:920-32. [DOI: 10.1016/j.jhep.2011.05.008] [Cited by in Crossref: 183] [Cited by in F6Publishing: 150] [Article Influence: 18.3] [Reference Citation Analysis]
39 Pisto P, Ukkola O, Santaniemi M, Kesäniemi YA. Plasma adiponectin--an independent indicator of liver fat accumulation. Metabolism 2011;60:1515-20. [PMID: 21565369 DOI: 10.1016/j.metabol.2011.03.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
40 Schie IW, Wu J, Weeks T, Zern MA, Rutledge JC, Huser T. Label-free imaging and analysis of the effects of lipolysis products on primary hepatocytes. J Biophotonics 2011;4:425-34. [PMID: 20878906 DOI: 10.1002/jbio.201000086] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
41 Sadik NA, Ahmed A, Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol. 2012;31:311-321. [PMID: 22249387 DOI: 10.1177/0960327111431091] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
42 Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S10-S20. [PMID: 21742296 DOI: 10.1016/s2210-7401(11)70003-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
43 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49:471-483. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 40.3] [Reference Citation Analysis]
44 Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. 2012;27:420-428. [PMID: 22596186 DOI: 10.1097/hco.0b013e328354829c] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
45 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
46 Overi D, Carpino G, Franchitto A, Onori P, Gaudio E. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells 2020;9:E590. [PMID: 32131439 DOI: 10.3390/cells9030590] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
47 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
48 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014;20:12945-55. [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 64] [Article Influence: 13.7] [Reference Citation Analysis]
49 Kitsios K, Papadopoulou M, Kosta K, Kadoglou N, Papagianni M, Tsiroukidou K. High-sensitivity C-reactive protein levels and metabolic disorders in obese and overweight children and adolescents. J Clin Res Pediatr Endocrinol 2013;5:44-9. [PMID: 23367494 DOI: 10.4274/Jcrpe.789] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Ruiz-Extremera Á, Carazo Á, Salmerón Á, León J, Casado J, Goicoechea A, Fernandez JM, Garofano M, Ocete E, Martín AB, Pavón E, Salmerón J. Factors associated with hepatic steatosis in obese children and adolescents. J Pediatr Gastroenterol Nutr 2011;53:196-201. [PMID: 21788762 DOI: 10.1097/MPG.0b013e3182185ac4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
51 Bozkurt L, Göbl CS, Tura A, Chmelik M, Prikoszovich T, Kosi L, Wagner O, Roden M, Pacini G, Gastaldelli A. Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One. 2012;7:e32710. [PMID: 22393439 DOI: 10.1371/journal.pone.0032710] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
52 Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010;4:623-635. [PMID: 20932147 DOI: 10.1586/egh.10.56] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
53 Chiang CH, Lai JS, Sheu JC, Yen LL, Liu CJ, Huang KC. The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. Obes Res Clin Pract. 2012;6:e1-e90. [PMID: 24331171 DOI: 10.1016/j.orcp.2011.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
54 Tessitore A, Mastroiaco V, Vetuschi A, Sferra R, Pompili S, Cicciarelli G, Barnabei R, Capece D, Zazzeroni F, Capalbo C, Alesse E. Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model. Oncotarget 2017;8:53482-94. [PMID: 28881825 DOI: 10.18632/oncotarget.18585] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
55 Dongiovanni P, Valenti L. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2017;18:E1534. [PMID: 28714900 DOI: 10.3390/ijms18071534] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
56 Shabani P, Emamgholipour S, Doosti M. CTRP1 in Liver Disease. Elsevier; 2017. pp. 1-23. [DOI: 10.1016/bs.acc.2016.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
57 Gherman CD, Mironiuc AI. Evaluation of serum adipokines in peripheral arterial occlusive disease. Mediators Inflamm 2012;2012:257808. [PMID: 22547903 DOI: 10.1155/2012/257808] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
58 Chang M, Yeh H, Tsou Y, Wang C, Cheng H, Sung C, Ho Y, Chen T, Yeh C. HCV Core-Induced Nonobese Hepatic Steatosis Is Associated With Hypoadiponectinemia and Is Ameliorated by Adiponectin Administration. Obesity 2012;20:1474-80. [DOI: 10.1038/oby.2012.45] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
59 Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774-788. [PMID: 20683968 DOI: 10.1002/hep.23719] [Cited by in Crossref: 606] [Cited by in F6Publishing: 546] [Article Influence: 55.1] [Reference Citation Analysis]
60 Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes. 2012;7:471-479. [PMID: 22962039 DOI: 10.1111/j.2047-6310.2012.00082.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
61 Gutiérrez-vidal R, Vega-badillo J, Reyes-fermín LM, Hernández-pérez HA, Sánchez-muñoz F, López-álvarez GS, Larrieta-carrasco E, Fernández-silva I, Méndez-sánchez N, Tovar AR, Villamil-ramírez H, Mejía-domínguez AM, Villarreal-molina T, Hernández-pando R, Campos-pérez F, Aguilar-salinas CA, Canizales-quinteros S. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women. Annals of Hepatology 2015;14:666-74. [DOI: 10.1016/s1665-2681(19)30761-6] [Cited by in Crossref: 19] [Article Influence: 3.2] [Reference Citation Analysis]
62 Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol. 2016;22:1461-1476. [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]
63 Francque SM. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. Eur Cardiol 2014;9:10-5. [PMID: 30310479 DOI: 10.15420/ecr.2014.9.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
64 Ben-Shlomo S, Einstein FH, Zvibel I, Atias D, Shlomai A, Halpern Z, Barzilai N, Fishman S. Perinephric and epididymal fat affect hepatic metabolism in rats. Obesity (Silver Spring) 2012;20:151-6. [PMID: 21818154 DOI: 10.1038/oby.2011.261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
65 Wu X, Shu L, Zhang Z, Li J, Zong J, Cheong LY, Ye D, Lam KSL, Song E, Wang C, Xu A, Hoo RLC. Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells. Adv Sci (Weinh) 2021;8:e2003721. [PMID: 34105268 DOI: 10.1002/advs.202003721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Gu H, Yang K, Shen Z, Jia K, Liu P, Pan M, Sun C. ER stress-induced adipocytes secrete-aldo-keto reductase 1B7-containing exosomes that cause nonalcoholic steatohepatitis in mice. Free Radic Biol Med 2021;163:220-33. [PMID: 33359683 DOI: 10.1016/j.freeradbiomed.2020.12.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
67 González-Reimers E, Santolaria-Fernández F, Martín-González MC, Fernández-Rodríguez CM, Quintero-Platt G. Alcoholism: a systemic proinflammatory condition. World J Gastroenterol 2014;20:14660-71. [PMID: 25356029 DOI: 10.3748/wjg.v20.i40.14660] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
68 Huang JF, Huang CF, Yu ML, Dai CY, Huang CI, Yeh ML, Hsieh MH, Yang JF, Hsieh MY, Lin ZY. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. J Gastroenterol Hepatol. 2011;26:530-535. [PMID: 21332548 DOI: 10.1111/j.1440-1746.2010.06438.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
69 Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17. [PMID: 27657051 DOI: 10.3390/ijms17091575] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 15.8] [Reference Citation Analysis]
70 Bian Z, Ma X. Liver fibrogenesis in non-alcoholic steatohepatitis. Front Physiol 2012;3:248. [PMID: 22934006 DOI: 10.3389/fphys.2012.00248] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
71 Híndi M, Levy C, Couto CA, Bejarano P, Mendes F. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol. 2013;47:e28-e32. [PMID: 23059407 DOI: 10.1097/mcg.0b013e318261e659] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
72 Konuma K, Itoh M, Suganami T, Kanai S, Nakagawa N, Sakai T, Kawano H, Hara M, Kojima S, Izumi Y. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS One. 2015;10:e0121528. [PMID: 25816330 DOI: 10.1371/journal.pone.0121528] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
73 Wai KK, Liang Y, Zhou L, Cai L, Liang C, Liu L, Lin X, Wu H, Lin J. The protective effects of Acanthus ilicifolius alkaloid A and its derivatives on pro- and anti-inflammatory cytokines in rats with hepatic fibrosis: Effects of A. ilicifolius Alkaloid A on Cytokines. Biotechnology and Applied Biochemistry 2015;62:537-46. [DOI: 10.1002/bab.1292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
74 Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Shirai H, Yao S, Yagi S, Kamo N, Seo S, Taura K, Okajima H, Uemoto S. Preoperative Visceral Adiposity and Muscularity Predict Poor Outcomes after Hepatectomy for Hepatocellular Carcinoma. Liver Cancer 2019;8:92-109. [PMID: 31019900 DOI: 10.1159/000488779] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
75 Pelusi S, Valenti L. Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. Liver Int 2019;39:250-6. [DOI: 10.1111/liv.13972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
76 Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71. [DOI: 10.1016/j.metabol.2016.01.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 7.6] [Reference Citation Analysis]
77 Hsu C, Liu W, Chao Y, Lin HH, Tseng T, Wang C, Chen D, Kao J. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. Hepatol Int 2015;9:231-42. [DOI: 10.1007/s12072-015-9616-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
78 Ali TM, Al Hadidi K. Chemerin is associated with markers of inflammation and predictors of atherosclerosis in Saudi subjects with metabolic syndrome and type 2 diabetes mellitus. Beni-Suef University Journal of Basic and Applied Sciences 2013;2:86-95. [DOI: 10.1016/j.bjbas.2013.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
79 De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4:375-385. [PMID: 20305757 DOI: 10.1007/s12072-009-9160-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
80 de Meijer VE, Le HD, Meisel JA, Sharma AK, Popov Y, Puder M. Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS One 2011;6:e25587. [PMID: 21980496 DOI: 10.1371/journal.pone.0025587] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
81 Lisi S, Gamucci O, Vottari T, Scabia G, Funicello M, Marchi M, Galli G, Arisi I, Brandi R, D'Onofrio M, Pinchera A, Santini F, Maffei M. Obesity-associated hepatosteatosis and impairment of glucose homeostasis are attenuated by haptoglobin deficiency. Diabetes. 2011;60:2496-2505. [PMID: 21873550 DOI: 10.2337/db10-1536] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
82 Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. 2013;133:1776-1783. [PMID: 23404222 DOI: 10.1002/ijc.28105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
83 Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Wu JC, Lin HC, Lee SD. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin Nutr 2011;30:647-52. [PMID: 21612848 DOI: 10.1016/j.clnu.2011.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
84 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
85 Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT. Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci Rep 2016;6:30799. [PMID: 27477870 DOI: 10.1038/srep30799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
86 Carazo A, León J, Casado J, Gila A, Delgado S, Martín A, Sanjuan L, Caballero T, Muñoz JA, Quiles R, Ruiz-Extremera A, Alcázar LM, Salmerón J. Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1. Obes Surg 2011;21:492-500. [PMID: 21240660 DOI: 10.1007/s11695-010-0353-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
87 Dou JP, Han ZY, Liu F, Cheng Z, Yu X, Yu J, Liang P. Beneficial body mass index to enhance survival outcomes in patients with early-stage hepatocellular carcinoma following microwave ablation treatment. Int J Hyperthermia 2020;37:110-8. [PMID: 31969030 DOI: 10.1080/02656736.2020.1712482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
88 Gracia-sancho J, Caparrós E, Fernández-iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:411-31. [DOI: 10.1038/s41575-020-00411-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
89 Petta S, Tripodo C, Grimaudo S, Cabibi D, Cammà C, Di Cristina A, Di Marco V, Di Vita G, Ingrao S, Mazzola A. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Dig Liver Dis. 2011;43:404-410. [PMID: 21324757 DOI: 10.1016/j.dld.2010.12.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
90 Harrison SA. Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution? Hepatology 2010;51:366-9. [DOI: 10.1002/hep.23473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
91 Goltz D, Schötta K, Zhou H, Fischer H. Nichtalkoholische Steatohepatitis mit Zirrhose bei jungen Erwachsenen mit hypothalamisch-hypophysärer Dysfunktion. Pathologe 2013;34:318-22. [DOI: 10.1007/s00292-012-1735-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
92 Cabrera D, Cabello-Verrugio C, Solís N, San Martín D, Cofré C, Pizarro M, Arab JP, Abrigo J, Campos F, Irigoyen B, Carrasco-Avino G, Bezares K, Riquelme V, Riquelme A, Arrese M, Barrera F. Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation. Int J Mol Sci 2018;19:E1339. [PMID: 29724029 DOI: 10.3390/ijms19051339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
93 Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, Di Stasio M, Paolisso G, Castello G, Colonna G. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One. 2012;7:e39486. [PMID: 22745767 DOI: 10.1371/journal.pone.0039486] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
94 Álvarez-Mercado AI, Bujaldon E, Gracia-Sancho J, Peralta C. The Role of Adipokines in Surgical Procedures Requiring Both Liver Regeneration and Vascular Occlusion. Int J Mol Sci 2018;19:E3395. [PMID: 30380727 DOI: 10.3390/ijms19113395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol. 2011;45:50-54. [PMID: 20717042 DOI: 10.1097/mcg.0b013e3181ec5c66] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
96 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Andrighetto LV, Poziomyck AK. SERUM LEPTIN LEVENS AND HEPATOCELLULAR CARCINOMA: REVIEW ARTICLE. Arq Bras Cir Dig 2016;29:276-8. [PMID: 28076486 DOI: 10.1590/0102-6720201600040015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
98 Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20:9217-9228. [PMID: 25071314 DOI: 10.3748/wjg.v20.i28.9217] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
99 Choi HY, Hwang SY, Lee CH, Hong HC, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic Fatty liver disease. Diabetes Metab J 2013;37:63-71. [PMID: 23439771 DOI: 10.4093/dmj.2013.37.1.63] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
100 Cubedo J, Padró T, Cinca J, Mata P, Alonso R, Badimon L. Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. Eur J Clin Invest 2014;44:266-75. [PMID: 24720534 DOI: 10.1111/eci.12229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
101 Marra F. Ghrelin and fibrogenesis: relief for a hungry liver. J Hepatol 2011;55:221-3. [PMID: 21334401 DOI: 10.1016/j.jhep.2011.01.027] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
102 Marra F, Parola M. Cells in the Liver—Functions in Health and Disease. In: Ginès P, Kamath PS, Arroyo V, editors. Chronic Liver Failure. Totowa: Humana Press; 2011. pp. 3-32. [DOI: 10.1007/978-1-60761-866-9_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Hernández-Bartolomé Á, López-Rodríguez R, García-Buey L, Martín-Vílchez S, Rodríguez-Muñoz Y, Borque MJ, González-Moreno L, Real-Martínez Y, Mendoza-Ridruejo J, Martín-Pérez E, Moreno-Otero R, Sanz-Cameno P. Intrahepatic angiopoietin-2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems. Liver Int 2017;37:1148-56. [PMID: 28027429 DOI: 10.1111/liv.13352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
104 Sauvant P, Cansell M, Atgié C. Vitamin A and lipid metabolism: relationship between hepatic stellate cells (HSCs) and adipocytes. J Physiol Biochem. 2011;67:487-496. [PMID: 21626400 DOI: 10.1007/s13105-011-0101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
105 Balasus D, Way M, Fusilli C, Mazza T, Morgan MY, Cervello M, Giannitrapani L, Soresi M, Agliastro R, Vinciguerra M, Montalto G. The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget 2016;7:86791-802. [PMID: 27888630 DOI: 10.18632/oncotarget.13558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
106 Britton LJ, Subramaniam VN, Crawford DH. Iron and non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22:8112-8122. [PMID: 27688653 DOI: 10.3748/wjg.v22.i36.8112] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 39] [Article Influence: 12.5] [Reference Citation Analysis]
107 Koot BG. van der Baan-Slootweg OH, Bohte AE, Nederveen AJ, van Werven JR, Tamminga-Smeulders CL, Merkus MP, Schaap FG, Jansen PL, Stoker J, Benninga MA. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity (Silver Spring). 2013;21:583-590. [PMID: 23592667 DOI: 10.1002/oby.20173] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
108 Trujillo-güiza ML, Señarís R. Leptin resistance during pregnancy is also exerted at the periphery†. Biology of Reproduction 2018;98:654-63. [DOI: 10.1093/biolre/ioy024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Dornelles CT, Goldani HA, Wilasco MI, Maurer RL, Kieling CO, Porowski M, Ferreira CT, Santos JL, Vieira SM, Silveira TR. Ghrelin, leptin and insulin in cirrhotic children and adolescents: relationship with cirrhosis severity and nutritional status. Regul Pept. 2013;180:26-32. [PMID: 23142314 DOI: 10.1016/j.regpep.2012.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
110 Karagiannides I, Golovatscka V, Bakirtzi K, Sideri A, Salas M, Stavrakis D, Polytarchou C, Iliopoulos D, Pothoulakis C, Bradesi S. Chronic unpredictable stress regulates visceral adipocyte-mediated glucose metabolism and inflammatory circuits in male rats. Physiol Rep 2014;2:e00284. [PMID: 24819750 DOI: 10.14814/phy2.284] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
111 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 576] [Article Influence: 57.9] [Reference Citation Analysis]
112 Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 2011;60:544-549. [PMID: 20580037 DOI: 10.1016/j.metabol.2010.05.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
113 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Reference Citation Analysis]
114 Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011;22:479-88. [PMID: 22002020 DOI: 10.1097/MOL.0b013e32834c7cfc] [Cited by in Crossref: 77] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
115 Barrera F, George J. Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. Drug Discovery Today: Disease Mechanisms 2013;10:e47-54. [DOI: 10.1016/j.ddmec.2013.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
116 Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 2012;61:454-62. [PMID: 22228717 DOI: 10.2337/db11-0613] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
117 Barazzoni R, Semolic A, Cattin MR, Zanetti M, Guarnieri G. Acylated ghrelin limits fat accumulation and improves redox state and inflammation markers in the liver of high-fat-fed rats. Obesity (Silver Spring) 2014;22:170-7. [PMID: 23512916 DOI: 10.1002/oby.20454] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
118 Shouval D, Friedman SL. Focusing on the past, present, and future of hepatology. J Hepatol. 2014;61:1196-1198. [PMID: 25195549 DOI: 10.1016/j.jhep.2014.08.039] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Caperna T, Shannon A, Garrett W, Ramsay T, Blomberg L, Elsasser T. Identification and characterization of a nuclear factor-κ B-p65 proteolytic fragment in nuclei of porcine hepatocytes in monolayer culture. Domestic Animal Endocrinology 2013;45:154-62. [DOI: 10.1016/j.domaniend.2013.08.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
120 Itoh M, Suganami T, Nakagawa N, Tanaka M, Yamamoto Y, Kamei Y, Terai S, Sakaida I, Ogawa Y. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol. 2011;179:2454-2463. [PMID: 21906580 DOI: 10.1016/j.ajpath.2011.07.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
121 Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver Int 2016;36:1563-79. [DOI: 10.1111/liv.13185] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 17.0] [Reference Citation Analysis]
122 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102:84-95. [PMID: 23545492 DOI: 10.1016/j.ygeno.2013.03.007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
124 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014;20:11033-53. [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 86] [Article Influence: 18.7] [Reference Citation Analysis]
125 Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, Paruthi J, Mantzoros CS. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34:377-412. [PMID: 23475416 DOI: 10.1210/er.2012-1053] [Cited by in Crossref: 149] [Cited by in F6Publishing: 129] [Article Influence: 18.6] [Reference Citation Analysis]
126 Silva T, Colombo G, Schiavon L. Adiponectin: A multitasking player in the field of liver diseases. Diabetes & Metabolism 2014;40:95-107. [DOI: 10.1016/j.diabet.2013.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
127 Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX, Jiang T, Levi M, Pruzanski M, Adorini L. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol. 2010;78:617-630. [PMID: 20631053 DOI: 10.1124/mol.110.064501] [Cited by in Crossref: 118] [Cited by in F6Publishing: 106] [Article Influence: 10.7] [Reference Citation Analysis]
128 Levin LM, Völzke H, Lerch MM, Kühn JP, Nauck M, Friedrich N, Zylla S. Associations of circulating chemerin and adiponectin concentrations with hepatic steatosis. Endocr Connect 2019;8:1097-107. [PMID: 31265993 DOI: 10.1530/EC-19-0300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
129 Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010;7:425-36. [DOI: 10.1038/nrgastro.2010.97] [Cited by in Crossref: 377] [Cited by in F6Publishing: 360] [Article Influence: 34.3] [Reference Citation Analysis]
130 Yu HC, Li SY, Cao MF, Jiang XY, Feng L, Zhao JJ, Gao L. Effects of chronic ethanol consumption on levels of adipokines in visceral adipose tissues and sera of rats. Acta Pharmacol Sin 2010;31:461-9. [PMID: 20208553 DOI: 10.1038/aps.2010.12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
131 Li Y, Ding WX. Adipose tissue autophagy and homeostasis in alcohol-induced liver injury. Liver Res 2017;1:54-62. [PMID: 29109891 DOI: 10.1016/j.livres.2017.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
132 Nobili V, Svegliati-baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology 2013;58:1218-29. [DOI: 10.1016/j.jhep.2012.12.003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 91] [Article Influence: 13.3] [Reference Citation Analysis]
133 Tilg H, Moschen A. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr Opin Clin Nutr Metab Care. 2010;13:391-396. [PMID: 20473151 DOI: 10.1097/MCO.0b013e32833a87cc] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
134 Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis. 2013;227:216-221. [PMID: 23332774 DOI: 10.1016/j.atherosclerosis.2012.12.029] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 9.6] [Reference Citation Analysis]
135 Mei M, Zhao L, Li Q, Chen Y, Huang A, Varghese Z, Moorhead JF, Zhang S, Powis SH, Li Q, Ruan XZ. Inflammatory stress exacerbates ectopic lipid deposition in C57BL/6J mice. Lipids Health Dis 2011;10:110. [PMID: 21718499 DOI: 10.1186/1476-511X-10-110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
136 Kasztelan-Szczerbinska B, Surdacka A, Slomka M, Rolinski J, Celinski K, Smolen A, Szczerbinski M. Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease. Mediators Inflamm. 2013;2013:148526. [PMID: 24259947 DOI: 10.1155/2013/148526] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
137 Orsi E, Grancini V, Menini S, Aghemo A, Pugliese G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Liver Int. 2017;37:950-962. [PMID: 27943508 DOI: 10.1111/liv.13337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 7.2] [Reference Citation Analysis]
138 García-álvarez M, Berenguer J, Micheloud D, Guzmán-fulgencio M, Catalán P, López JC, Cosín J, Miralles P, Carrero-gras A, Resino S. Sustained Virologic Response Decreases Serum Markers of Angiogenesis, Inflammation, and Fibrosis in HIV/HCV-Coinfected Patients on Hepatitis C Virus Therapy. AIDS Patient Care and STDs 2011;25:131-3. [DOI: 10.1089/apc.2010.0387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid signalling: has it got rhythm? Br J Pharmacol 2010;160:530-43. [PMID: 20590563 DOI: 10.1111/j.1476-5381.2010.00790.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
140 Sawada K, Ohtake T, Hasebe T, Abe M, Tanaka H, Ikuta K, Suzuki Y, Fujiya M, Hasebe C, Kohgo Y. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice: FAs make the pro-inflammatory state of NAFLD. Hepatol Res 2014;44:920-34. [DOI: 10.1111/hepr.12199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
141 Dongiovanni P, Meroni M, Baselli GA, Bassani GA, Rametta R, Pietrelli A, Maggioni M, Facciotti F, Trunzo V, Badiali S, Fargion S, Gatti S, Valenti L. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clin Sci (Lond) 2017;131:1301-15. [PMID: 28468951 DOI: 10.1042/CS20170175] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 7.8] [Reference Citation Analysis]
142 Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953-966. [PMID: 24750664 DOI: 10.1111/liv.12570] [Cited by in Crossref: 164] [Cited by in F6Publishing: 145] [Article Influence: 23.4] [Reference Citation Analysis]
143 Yu SJ, Kim W, Kim D, Yoon JH, Lee K, Kim JH, Cho EJ, Lee JH, Kim HY, Kim YJ. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine (Baltimore). 2015;94:e2159. [PMID: 26632897 DOI: 10.1097/md.0000000000002159] [Cited by in Crossref: 46] [Cited by in F6Publishing: 22] [Article Influence: 9.2] [Reference Citation Analysis]
144 Grancini V, Resi V, Palmieri E, Pugliese G, Orsi E. Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacol Res. 2019;141:556-573. [PMID: 30690071 DOI: 10.1016/j.phrs.2019.01.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
145 Tan X, Sun X, Li Q, Zhao Y, Zhong W, Sun X, Jia W, McClain CJ, Zhou Z. Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice. Am J Pathol 2012;181:1279-86. [PMID: 22841822 DOI: 10.1016/j.ajpath.2012.06.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
146 Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int 2012;2012:172894. [PMID: 22666632 DOI: 10.1155/2012/172894] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
147 Laouirem S, Sannier A, Norkowski E, Cauchy F, Doblas S, Rautou PE, Albuquerque M, Garteiser P, Sognigbé L, Raffenne J, van Beers BE, Soubrane O, Bedossa P, Cros J, Paradis V. Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. Oncogene 2019;38:3033-46. [PMID: 30575815 DOI: 10.1038/s41388-018-0597-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
148 Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;1801:299-310. [PMID: 19857603 DOI: 10.1016/j.bbalip.2009.10.007] [Cited by in Crossref: 178] [Cited by in F6Publishing: 174] [Article Influence: 14.8] [Reference Citation Analysis]
149 de Castro IF, Berenguer J, Micheloud D, Guzmán-Fulgencio M, Cosín J, Alvarez E, López JC, Miralles P, García-Álvarez M, Resino S. Serum levels of adipokines in HIV/HCV co-infected patients and their association with insulin resistance and liver disease severity. J Infect 2010;61:499-501. [PMID: 20728222 DOI: 10.1016/j.jinf.2010.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
150 Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-S90. [PMID: 25443348 DOI: 10.1016/j.jhep.2014.07.010] [Cited by in Crossref: 124] [Cited by in F6Publishing: 103] [Article Influence: 17.7] [Reference Citation Analysis]
151 Tönjes A, Fasshauer M, Kratzsch J, Stumvoll M, Blüher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 2010;5:e13911. [PMID: 21085476 DOI: 10.1371/journal.pone.0013911] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 7.3] [Reference Citation Analysis]
152 Mencarelli A, Distrutti E, Renga B, D’Amore C, Cipriani S, Palladino G, Donini A, Ricci P, Fiorucci S. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6:e22978. [PMID: 21829567 DOI: 10.1371/journal.pone.0022978] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
153 Arano T, Nakagawa H, Ikeda H, Koike K. Adiponectin in chronic hepatitis C. Clin J Gastroenterol 2013;6:259-63. [DOI: 10.1007/s12328-013-0410-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S. Translational approaches: From fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol. 2014;20:9038-9049. [PMID: 25083077 DOI: 10.3748/wjg.v20.i27.9038] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
155 Elpek GÖ. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol 2014;20:7260-76. [PMID: 24966597 DOI: 10.3748/wjg.v20.i23.7260] [Cited by in CrossRef: 161] [Cited by in F6Publishing: 140] [Article Influence: 26.8] [Reference Citation Analysis]
156 Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol 2018;29:14-21. [PMID: 29391303 DOI: 10.5152/tjg.2018.17330] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 19.7] [Reference Citation Analysis]
157 Salunkhe SA, Chitkara D, Mahato RI, Mittal A. Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. Adv Drug Deliv Rev 2021;173:394-415. [PMID: 33831474 DOI: 10.1016/j.addr.2021.04.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Chiang CH, Lai JS, Hung SH, Lee LT, Sheu JC, Huang KC. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring). 2013;21:291-296. [PMID: 23404868 DOI: 10.1002/oby.20000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
159 Li Y, Ding L, Hassan W, Abdelkader D, Shang J. Adipokines and hepatic insulin resistance. J Diabetes Res 2013;2013:170532. [PMID: 23762871 DOI: 10.1155/2013/170532] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
160 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269. [PMID: 23394092 DOI: 10.2174/1381612811399990344] [Reference Citation Analysis]
161 Henry RK. Growth Hormone Deficiency and Nonalcoholic Fatty Liver Disease with Insights from Humans and Animals: Pediatric Implications. Metabolic Syndrome and Related Disorders 2018;16:507-13. [DOI: 10.1089/met.2018.0056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Chen Y, Varghese Z, Ruan XZ. The molecular pathogenic role of inflammatory stress in dysregulation of lipid homeostasis and hepatic steatosis. Genes Dis 2014;1:106-12. [PMID: 30258859 DOI: 10.1016/j.gendis.2014.07.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
163 Chang JS, Kim TH, Nguyen TT, Park KS, Kim N, Kong ID. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr Gerontol Int 2017;17:2266-73. [PMID: 28394089 DOI: 10.1111/ggi.13030] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
164 Hammoutene A, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol. 2019;70:1278-1291. [PMID: 30797053 DOI: 10.1016/j.jhep.2019.02.012] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 34.0] [Reference Citation Analysis]
165 Naveau S, Cassard-Doulcier AM, Njiké-Nakseu M, Bouchet-Delbos L, Barri-Ova N, Boujedidi H, Dauvois B, Balian A, Maitre S, Prévot S, Dagher I, Agostini H, Grangeot-Keros L, Emilie D, Perlemuter G. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease. J Hepatol 2010;52:895-902. [PMID: 20399524 DOI: 10.1016/j.jhep.2010.01.029] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
166 Kennedy JIC, Askelund KJ, Premkumar R, Phillips ARJ, Murphy R, Windsor JA, Petrov MS. Leptin Is Associated With Persistence of Hyperglycemia in Acute Pancreatitis: A Prospective Clinical Study. Medicine (Baltimore) 2016;95:e2382. [PMID: 26871770 DOI: 10.1097/MD.0000000000002382] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 4.4] [Reference Citation Analysis]
167 Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010;2010:837419. [PMID: 20300479 DOI: 10.1155/2010/837419] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
168 Hsu CS, Kao JH. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. J Formos Med Assoc. 2012;111:527-535. [PMID: 23089687 DOI: 10.1016/j.jfma.2012.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
169 Abu-tair L, Doron S, Mahamid M, Amer J, Safadi R. Leptin modulates lymphocytes' adherence to hepatic stellate cells is associated with oxidative status alterations. Mitochondrion 2013;13:473-80. [DOI: 10.1016/j.mito.2012.10.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
170 Kawaguchi T, Shiba N, Maeda T, Matsugaki T, Takano Y, Itou M, Sakata M, Taniguchi E, Nagata K, Sata M. Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: a pilot study. J Gastroenterol. 2011;46:746-757. [PMID: 21340530 DOI: 10.1007/s00535-011-0378-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
171 Abdel-Razik A, Mousa N, Abdel-Aziz M, Elhelaly R, Elzehery R, Zalata K, Elkashef W, Fouda O, Awad M, Hafez M, Eldars W. Elevated serum α-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story. Eur J Gastroenterol Hepatol 2016;28:313-22. [PMID: 26618566 DOI: 10.1097/MEG.0000000000000534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
172 Lee JH, Lee JJ, Cho WK, Yim NH, Kim HK, Yun B, Ma JY. KBH-1, an herbal composition, improves hepatic steatosis and leptin resistance in high-fat diet-induced obese rats. BMC Complement Altern Med. 2016;16:355. [PMID: 27618865 DOI: 10.1186/s12906-016-1265-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
173 Lombardi R, Pisano G, Fargion S. Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD. Int J Mol Sci. 2016;17:548. [PMID: 27077854 DOI: 10.3390/ijms17040548] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
174 Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med. 2017;32:213-228. [PMID: 28171717 DOI: 10.3904/kjim.2016.268] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
175 Abe Y, Kawakami A, Osaka M, Uematsu S, Akira S, Shimokado K, Sacks FM, Yoshida M. Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes. Arterioscler Thromb Vasc Biol 2010;30:2242-8. [PMID: 20829510 DOI: 10.1161/ATVBAHA.110.210427] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
176 Aragón-Herrera A, Feijóo-Bandín S, Moraña-Fernández S, Anido-Varela L, Roselló-Lletí E, Portolés M, Tarazón E, Lage R, Moscoso I, Barral L, Bani D, Bigazzi M, Gualillo O, González-Juanatey JR, Lago F. Relaxin has beneficial effects on liver lipidome and metabolic enzymes. FASEB J 2021;35:e21737. [PMID: 34143495 DOI: 10.1096/fj.202002620RR] [Reference Citation Analysis]
177 Duval C, Thissen U, Keshtkar S, Accart B, Stienstra R, Boekschoten MV, Roskams T, Kersten S, Müller M. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes. 2010;59:3181-3191. [PMID: 20858684 DOI: 10.2337/db10-0224] [Cited by in Crossref: 124] [Cited by in F6Publishing: 114] [Article Influence: 11.3] [Reference Citation Analysis]
178 Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer. 2011;129:2226-2235. [PMID: 21170963 DOI: 10.1002/ijc.25861] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
179 Imai K, Takai K, Maeda T, Watanabe S, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment. Oncotarget 2018;9:14058-67. [PMID: 29581826 DOI: 10.18632/oncotarget.24500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
180 Pacifico L, Chiesa C, Anania C, De Merulis A, Osborn JF, Romaggioli S, Gaudio E. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 2014;20:9055-71. [PMID: 25083079 DOI: 10.3748/wjg.v20.i27.9055] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
181 Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711. [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
182 Karagiannides I, Bakirtzi K, Kokkotou E, Stavrakis D, Margolis KG, Thomou T, Giorgadze N, Kirkland JL, Pothoulakis C. Role of substance P in the regulation of glucose metabolism via insulin signaling-associated pathways. Endocrinology 2011;152:4571-80. [PMID: 22009727 DOI: 10.1210/en.2011-1170] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
183 Pickett-Blakely O, Young K, Carr RM. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cell Mol Gastroenterol Hepatol. 2018;6:451-462. [PMID: 30294653 DOI: 10.1016/j.jcmgh.2018.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
184 Malavazos AE, Gobbo G, Zelaschi RF, Cereda E. Lifestyle intervention and fatty liver disease: the importance of both disrupting inflammation and reducing visceral fat. Hepatology 2010;51:1091-2. [PMID: 19960554 DOI: 10.1002/hep.23409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
185 Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. J Clin Transl Hepatol. 2015;3:9-16. [PMID: 26356325 DOI: 10.14218/jcth.2015.00001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
186 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 69] [Article Influence: 12.7] [Reference Citation Analysis]
187 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
188 Khattab MA, Eslam M, Aly MM, Shatat M, Hussen A, Moussa YI, Elsaghir G, Abdalhalim H, Aly A, Gaber S, Harrison SA. Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4. J Clin Gastroenterol 2012;46:871-9. [PMID: 22664476 DOI: 10.1097/MCG.0b013e318256b68a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
189 Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016;65:1026-37. [DOI: 10.1016/j.metabol.2015.08.018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 11.6] [Reference Citation Analysis]
190 Musso G, Cassader M, De Michieli F, Saba F, Bo S, Gambino R. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr. 2011;94:1033-1042. [PMID: 21865331 DOI: 10.3945/ajcn.111.015610] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
191 Wattacheril J, Rose KL, Hill S, Lanciault C, Murray CR, Washington K, Williams B, English W, Spann M, Clements R, Abumrad N, Flynn CR. Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle. Hepatol Res 2017;47:1469-83. [PMID: 28258704 DOI: 10.1111/hepr.12885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
192 Wang ZG, Dou XB, Zhou ZX, Song ZY. Adipose tissue-liver axis in alcoholic liver disease. World J Gastrointest Pathophysiol 2016;7:17-26. [PMID: 26909225 DOI: 10.4291/wjgp.v7.i1.17] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
193 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Practice & Research Clinical Gastroenterology 2011;25:231-44. [DOI: 10.1016/j.bpg.2011.02.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
195 Capone F, Guerriero E, Colonna G, Maio P, Mangia A, Marfella R, Paolisso G, Izzo F, Potenza N, Tomeo L, Castello G, Costantini S. The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. PLoS One 2015;10:e0134594. [PMID: 26226632 DOI: 10.1371/journal.pone.0134594] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
196 von Loeffelholz C, Lieske S, Neuschäfer-Rube F, Willmes DM, Raschzok N, Sauer IM, König J, Fromm MF, Horn P, Chatzigeorgiou A, Pathe-Neuschäfer-Rube A, Jordan J, Pfeiffer AFH, Mingrone G, Bornstein SR, Stroehle P, Harms C, Wunderlich FT, Helfand SL, Bernier M, de Cabo R, Shulman GI, Chavakis T, Püschel GP, Birkenfeld AL. The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism. Hepatology 2017;66:616-30. [PMID: 28133767 DOI: 10.1002/hep.29089] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
197 García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, González-González JA, Maldonado-Garza HJ, Villarreal-Pérez JZ. Plasma cytokine levels imbalance in cirrhotic patients with impaired glucose tolerance and diabetes mellitus. A prospective study. Ann Hepatol 2014;13:403-10. [PMID: 24927611 [PMID: 24927611 DOI: 10.1016/s1665-2681(19)30847-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
198 Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298:G440-G445. [PMID: 20093562 DOI: 10.1152/ajpgi.00322.2009] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 9.0] [Reference Citation Analysis]
199 Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, Yin S, Lafdil F, Gao B. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology. 2011;54:846-856. [PMID: 21725996 DOI: 10.1002/hep.24517] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 11.8] [Reference Citation Analysis]
200 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Reference Citation Analysis]
201 Voumvouraki A, Koulentaki M, Notas G, Sfakianaki O, Kouroumalis E. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med. 2011;22:77-83. [PMID: 21238899 DOI: 10.1016/j.ejim.2010.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
202 Mastroianni CM, Lichtner M, Mascia C, Zuccalà P, Vullo V. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci 2014;15:9184-208. [PMID: 24865485 DOI: 10.3390/ijms15069184] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
203 Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G697-G702. [PMID: 21350183 DOI: 10.1152/ajpgi.00426.2010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 10.6] [Reference Citation Analysis]
204 Chen BY, Qu P, Tie R, Zhu MZ, Zhu XX, Yu J. Protecting effects of vasonatrin peptide against carbon tetrachloride-induced liver fibrosis. Regul Pept 2010;164:139-43. [PMID: 20619296 DOI: 10.1016/j.regpep.2010.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
205 Micheloud D, Berenguer J, Guzmán-fulgencio M, Campos Y, García-álvarez M, Catalán P, Cosín J, Miralles P, López JC, Resino S. European Mitochondrial DNA Haplogroups and Metabolic Disorders in HIV/HCV-Coinfected Patients on Highly Active Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 2011;58:371-8. [DOI: 10.1097/qai.0b013e31822d2629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
206 Guiu B, Crevisy-girod E, Binquet C, Duvillard L, Masson D, Lepage C, Hamza S, Krausé D, Verges B, Minello A, Cercueil J, Hillon P, Petit J. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol 2012;22:855-63. [DOI: 10.1007/s00330-011-2326-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
207 Fisher A, Southcott E, Li R, Srikusalanukul W, Davis M, Smith P. Serum resistin in older patients with hip fracture: Relationship with comorbidity and biochemical determinants of bone metabolism. Cytokine 2011;56:157-66. [DOI: 10.1016/j.cyto.2011.06.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
208 Kema VH, Mojerla NR, Khan I, Mandal P. Effect of alcohol on adipose tissue: a review on ethanol mediated adipose tissue injury. Adipocyte 2015;4:225-31. [PMID: 26451277 DOI: 10.1080/21623945.2015.1017170] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
209 Honsawek S, Chayanupatkul M, Chongsrisawat V, Theamboonlers A, Praianantathavorn K, Udomsinprasert W, Vejchapipat P, Poovorawan Y. Serum adiponectin and transient elastography as non-invasive markers for postoperative biliary atresia. BMC Gastroenterol. 2011;11:16. [PMID: 21356120 DOI: 10.1186/1471-230x-11-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
210 Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 2019;282:110-20. [PMID: 30731283 DOI: 10.1016/j.atherosclerosis.2019.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 18.0] [Reference Citation Analysis]
211 Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S. PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis. 2013;45:619-624. [PMID: 23333103 DOI: 10.1016/j.dld.2012.12.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
212 Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology 2013;218:R25-36. [DOI: 10.1530/joe-13-0201] [Cited by in Crossref: 155] [Cited by in F6Publishing: 72] [Article Influence: 19.4] [Reference Citation Analysis]
213 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013;19:5250-69. [PMID: 23394092 DOI: 10.2174/13816128113199990344] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 13.4] [Reference Citation Analysis]
214 Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016;17:68-80. [PMID: 26597657 DOI: 10.1111/obr.12333] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
215 Scolaro L, Cassone M, Kolaczynski JW, Otvos L Jr, Surmacz E. Leptin-based therapeutics. Expert Rev Endocrinol Metab 2010;5:875-89. [PMID: 30780830 DOI: 10.1586/eem.10.61] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
216 Aleffi S, Navari N, Delogu W, Galastri S, Novo E, Rombouts K, Pinzani M, Parola M, Marra F. Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G210-G219. [PMID: 21252047 DOI: 10.1152/ajpgi.00047.2010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
217 Bellan M, Colletta C, Barbaglia MN, Salmi L, Clerici R, Mallela VR, Castello LM, Saglietti G, Carnevale Schianca GP, Minisini R, Pirisi M. Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms. Diabetes Metab J 2019;43:700-10. [PMID: 31694082 DOI: 10.4093/dmj.2018.0201] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
218 Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F, Ferrannini E, Loguercio C, Lonardo A, Marra F, Mancini M, Miele L, Nobili V, Baroni GS, Alessandro F, Ballestri S, Rossana Brunetto M, Coco B, Grieco A, Fargion S, Kondili L, Nascimbeni F, Prinster A, Romagnoli D, Taddei S, Vanni E, Vella S. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease 2016;48:333-42. [DOI: 10.1016/j.dld.2015.10.027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
219 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 247] [Cited by in F6Publishing: 219] [Article Influence: 27.4] [Reference Citation Analysis]
220 Parola M, Marra F. Adipokines and Redox Signaling: Impact on Fatty Liver Disease. Antioxidants & Redox Signaling 2011;15:461-83. [DOI: 10.1089/ars.2010.3848] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
221 Guri AJ, Bassaganya-Riera J. Systemic effects of white adipose tissue dysregulation and obesity-related inflammation. Obesity (Silver Spring) 2011;19:689-700. [PMID: 20930712 DOI: 10.1038/oby.2010.230] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
222 Keane JT, Elangovan H, Stokes RA, Gunton JE. Vitamin D and the Liver-Correlation or Cause? Nutrients 2018;10:E496. [PMID: 29659559 DOI: 10.3390/nu10040496] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
223 Khattab MA, Eslam M, Mousa YI, Ela-adawy N, Fathy S, Shatat M, Abd-aalhalim H, Kamal A, Sharawe MA. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Annals of Hepatology 2012;11:487-94. [DOI: 10.1016/s1665-2681(19)31462-0] [Cited by in Crossref: 32] [Article Influence: 3.6] [Reference Citation Analysis]
224 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 657] [Article Influence: 259.0] [Reference Citation Analysis]
225 Kim JS, Lê KA, Mahurkar S, Davis JN, Goran MI. Influence of elevated liver fat on circulating adipocytokines and insulin resistance in obese Hispanic adolescents. Pediatr Obes 2012;7:158-64. [PMID: 22434756 DOI: 10.1111/j.2047-6310.2011.00014.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
226 Loor J. Genomics of metabolic adaptations in the peripartal cow. Animal 2010;4:1110-39. [DOI: 10.1017/s1751731110000960] [Cited by in Crossref: 80] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
227 Kukla M, Berdowska A, Stygar D, Gabriel A, Mazur W, Łogiewa-Bazger B, Sobala-Szczygieł B, Bułdak RJ, Rokitka M, Zajęcki W, Kępa L, Sawczyn T, Zwirska-Korczala K. Serum FGF21 and RBP4 levels in patients with chronic hepatitis C. Scand J Gastroenterol 2012;47:1037-47. [PMID: 22670657 DOI: 10.3109/00365521.2012.694901] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
228 Guenther M, James R, Marks J, Zhao S, Szabo A, Kidambi S. Adiposity distribution influences circulating adiponectin levels. Transl Res 2014;164:270-7. [PMID: 24811003 DOI: 10.1016/j.trsl.2014.04.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
229 Reccia I, Kumar J, Akladios C, Virdis F, Pai M, Habib N, Spalding D. Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism. 2017;72:94-108. [PMID: 28641788 DOI: 10.1016/j.metabol.2017.04.011] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 21.3] [Reference Citation Analysis]
230 Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol. 2011;46:91-97. [PMID: 20809771 DOI: 10.3109/00365521.2010.516452] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 5.9] [Reference Citation Analysis]
231 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
233 Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195-206. [PMID: 21497738 DOI: 10.1016/j.bpg] [Reference Citation Analysis]
234 Nakagawa H, Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol. 2012;18:4071-4081. [PMID: 22919237 DOI: 10.3748/wjg.v18.i31.4071] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 73] [Article Influence: 10.4] [Reference Citation Analysis]
235 Nkontchou G, Bastard JP, Ziol M, Aout M, Cosson E, Ganne-Carrie N, Grando-Lemaire V, Roulot D, Capeau J, Trinchet JC, Vicaut E, Beaugrand M. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010;53:827-33. [PMID: 20728234 DOI: 10.1016/j.jhep.2010.04.035] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
236 Gottlieb A, Canbay A. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. Cells 2019;8:E1358. [PMID: 31671697 DOI: 10.3390/cells8111358] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
237 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203. [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21] [Cited by in Crossref: 318] [Cited by in F6Publishing: 276] [Article Influence: 28.9] [Reference Citation Analysis]
238 Elias-Miró M, Mendes-Braz M, Cereijo R, Villarroya F, Jiménez-Castro MB, Gracia-Sancho J, Guixé-Muntet S, Massip-Salcedo M, Domingo JC, Bermudo R, Rodés J, Peralta C. Resistin and visfatin in steatotic and non-steatotic livers in the setting of partial hepatectomy under ischemia-reperfusion. J Hepatol 2014;60:87-95. [PMID: 23968888 DOI: 10.1016/j.jhep.2013.07.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
239 Choudhary NS, Duseja A, Kalra N, Das A, Dhiman RK, Chawla YK. Correlation of adipose tissue with liver histology in Asian Indian patients with nonalcoholic fatty liver disease (NAFLD). Annals of Hepatology 2012;11:478-86. [DOI: 10.1016/s1665-2681(19)31461-9] [Cited by in Crossref: 31] [Article Influence: 3.4] [Reference Citation Analysis]
240 Aubert J, Begriche K, Knockaert L, Robin M, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clinics and Research in Hepatology and Gastroenterology 2011;35:630-7. [DOI: 10.1016/j.clinre.2011.04.015] [Cited by in Crossref: 173] [Cited by in F6Publishing: 153] [Article Influence: 17.3] [Reference Citation Analysis]
241 Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig Dis 2011;29:243-8. [PMID: 21734391 DOI: 10.1159/000323928] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
242 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
243 Durazzo M, Belci P, Niro G, Collo A, Grisoglio E, Ambrogio V, Spandre M, Fontana R, Gambino R, Cassader M. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis. J Endocrinol Invest. 2013;36:600-605. [PMID: 23449040 DOI: 10.3275/8883] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
244 Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, Karslioglu Y, Bagci S. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Annals of Hepatology 2013;12:380-7. [DOI: 10.1016/s1665-2681(19)31338-9] [Cited by in Crossref: 29] [Article Influence: 3.6] [Reference Citation Analysis]
245 Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010;7:425-436. [PMID: 20585339 DOI: 10.1038/nrgastro. 2010.97] [Reference Citation Analysis]
246 Deng Y, Wang H, Lu Y, Liu S, Zhang Q, Huang J, Zhu R, Yang J, Zhang R, Zhang D, Shen W, Ning G, Yang Y. Identification of Chemerin as a Novel FXR Target Gene Down-Regulated in the Progression of Nonalcoholic Steatohepatitis. Endocrinology 2013;154:1794-801. [DOI: 10.1210/en.2012-2126] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
247 Svinka J, Mikulits W, Eferl R. STAT3 in hepatocellular carcinoma: new perspectives. Hepatic Oncol. 2013;1:107-120. [PMID: 30190945 DOI: 10.2217/hep.13.7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
248 Rogal J, Binder C, Kromidas E, Roosz J, Probst C, Schneider S, Schenke-Layland K, Loskill P. WAT-on-a-chip integrating human mature white adipocytes for mechanistic research and pharmaceutical applications. Sci Rep 2020;10:6666. [PMID: 32313039 DOI: 10.1038/s41598-020-63710-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
249 Liu D, Li S, Li Z. Adiponectin: A biomarker for chronic hepatitis C? Cytokine 2017;89:27-33. [PMID: 26683021 DOI: 10.1016/j.cyto.2015.10.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
250 Namachivayam A, Valsala Gopalakrishnan A. A review on molecular mechanism of alcoholic liver disease. Life Sci 2021;274:119328. [PMID: 33711388 DOI: 10.1016/j.lfs.2021.119328] [Reference Citation Analysis]
251 Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011;25:195-206. [PMID: 21497738 DOI: 10.1016/j.bpg.2011.02.005] [Cited by in Crossref: 525] [Cited by in F6Publishing: 478] [Article Influence: 52.5] [Reference Citation Analysis]
252 Rachakonda V, Gabbert C, Raina A, Li H, Malik S, DeLany JP, Behari J. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. Alcohol Clin Exp Res. 2014;38:2712-2721. [PMID: 25421508 DOI: 10.1111/acer.12558] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
253 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 484] [Article Influence: 59.6] [Reference Citation Analysis]
254 Wang W, Yang GJ, Zhang J, Chen C, Jia ZY, Li J, Xu WD. Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles. Arthritis Res Ther 2016;18:244. [PMID: 27770826 DOI: 10.1186/s13075-016-1139-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
255 Darlyuk-Saadon I, Bai C, Heng CKM, Gilad N, Yu WP, Lim PY, Cazenave-Gassiot A, Zhang Y, Wong WSF, Engelberg D. Active p38α causes macrovesicular fatty liver in mice. Proc Natl Acad Sci U S A 2021;118:e2018069118. [PMID: 33811139 DOI: 10.1073/pnas.2018069118] [Reference Citation Analysis]
256 Grasso A, Malfatti F, Andraghetti G, Marenco S, Mazzucchelli C, Labanca S, Cordera R, Testa R, Picciotto A. HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients. Gastroenterol Res Pract 2015;2015:975695. [PMID: 25821463 DOI: 10.1155/2015/975695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
257 Gonciarz M, Bielański W, Partyka R, Brzozowski T, Konturek PC, Eszyk J, Celiński K, Reiter RJ, Konturek SJ. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin: Melatonin in nonalcoholic steatohepatitis. Journal of Pineal Research 2013;54:154-61. [DOI: 10.1111/j.1600-079x.2012.01023.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
258 Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7:251-264. [PMID: 20368739 DOI: 10.1038/nrgastro.2010.41] [Cited by in Crossref: 426] [Cited by in F6Publishing: 369] [Article Influence: 38.7] [Reference Citation Analysis]
259 Keinicke H, Sun G, Mentzel CMJ, Fredholm M, John LM, Andersen B, Raun K, Kjaergaard M. FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. Endocr Connect 2020;9:755-68. [PMID: 32688339 DOI: 10.1530/EC-20-0152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
260 Delogu W, Caligiuri A, Provenzano A, Rosso C, Bugianesi E, Coratti A, Macias-Barragan J, Galastri S, Di Maira G, Marra F. Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation. Dig Liver Dis 2019;51:1400-8. [PMID: 31005555 DOI: 10.1016/j.dld.2019.03.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
261 Kukla M, Mazur W, Bułdak RJ, Żwirska-korczala K. Potential Role of Leptin, Adiponectin and Three Novel Adipokines—Visfatin, Chemerin and Vaspin—in Chronic Hepatitis. Mol Med 2011;17:1397-410. [DOI: 10.2119/molmed.2010.00105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
262 Latief U, Ahmad R. Herbal remedies for liver fibrosis: A review on the mode of action of fifty herbs. J Tradit Complement Med. 2018;8:352-360. [PMID: 29992106 DOI: 10.1016/j.jtcme.2017.07.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
263 Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Shirai H, Yagi S, Kamo N, Okajima H, Uemoto S. Impact of Skeletal Muscle Mass Index, Intramuscular Adipose Tissue Content, and Visceral to Subcutaneous Adipose Tissue Area Ratio on Early Mortality of Living Donor Liver Transplantation. Transplantation. 2017;101:565-574. [PMID: 27926595 DOI: 10.1097/tp.0000000000001587] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 12.8] [Reference Citation Analysis]
264 Stout MB, Liu L, Belury MA. Hepatic steatosis by dietary-conjugated linoleic acid is accompanied by accumulation of diacylglycerol and increased membrane-associated protein kinase C ε in mice. Mol Nutr Food Res 2011;55:1010-7. [DOI: 10.1002/mnfr.201000413] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
265 Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018;4:55-71. [PMID: 29904722 DOI: 10.5114/ceh.2018.75955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
266 Akbal E, Koçak E, Taş A, Yüksel E, Köklü S. Visfatin levels in nonalcoholic fatty liver disease. J Clin Lab Anal. 2012;26:115-119. [PMID: 22467327 DOI: 10.1002/jcla.21491] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
267 Kawaguchi T, Shiba N, Takano Y, Maeda T, Sata M. Hybrid training of voluntary and electrical muscle contractions decreased fasting blood glucose and serum interleukin-6 levels in elderly people: a pilot study. Appl Physiol Nutr Metab 2011;36:276-83. [DOI: 10.1139/h10-108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
268 Chen L, Liu W, Lai S, Li Y, Wang X, Zhang H. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol 2013;25:935-41. [PMID: 23470357 DOI: 10.1097/MEG.0b013e32835fa988] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
269 Wu CF, Lin YL, Huang YT. Hepatitis C virus core protein stimulates fibrogenesis in hepatic stellate cells involving the obese receptor. J Cell Biochem. 2013;114:541-550. [PMID: 22961938 DOI: 10.1002/jcb.24392] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
270 Moctezuma-Velázquez C, García-Juárez I, Soto-Solís R, Hernández-Cortés J, Torre A. Nutritional assessment and treatment of patients with liver cirrhosis. Nutrition. 2013;29:1279-1285. [PMID: 23867207 DOI: 10.1016/j.nut.2013.03.017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
271 Badar S, Badar S, Khubaib B, Khubaib B, Idrees M, Idrees M, Hussain A, Hussain A, Awan Z, Awan Z, Butt S, Butt S, Afzal S, Afzal S, Akram M, Akram M, Fatima Z, Fatima Z, Aftab M, Aftab M, Saleem S, Saleem S, Munir S, Munir S, Rauff B, Rauff B, Naudhani M, Naudhani M, Liaquat A, Ali L, Ali M, Ali M, Rehman I, Rehman I. Association of Hepatitis C Virus With Insulin Resistance: Evidences From Animal Studies and Clinical Studie. Hepat Mon 2012;12:11-5. [DOI: 10.5812/hepatmon.4295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
272 Chang ML, Yang Z, Yang SS. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. Int J Mol Sci 2020;21:E8308. [PMID: 33167521 DOI: 10.3390/ijms21218308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
273 Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773-794. [PMID: 21145849 DOI: 10.1016/j.jhep.2010.11.006] [Cited by in Crossref: 308] [Cited by in F6Publishing: 246] [Article Influence: 28.0] [Reference Citation Analysis]
274 Hardy T, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol. 2015;31:175-183. [PMID: 25774446 DOI: 10.1097/mog.0000000000000175] [Cited by in Crossref: 61] [Cited by in F6Publishing: 30] [Article Influence: 12.2] [Reference Citation Analysis]
275 Karagozian R, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 2014;63:607-17. [DOI: 10.1016/j.metabol.2014.01.011] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 14.6] [Reference Citation Analysis]
276 Nakagawa H, Fujiwara N, Tateishi R, Arano T, Nakagomi R, Kondo M, Minami T, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Shiina S, Yoshida H, Koike K. Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patients. J Gastroenterol Hepatol 2015;30:379-88. [PMID: 25168107 DOI: 10.1111/jgh.12719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
277 García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Maldonado-Garza HJ, Villarreal-Pérez JZ. The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol. 2015;14:780-788. [PMID: 26436350 DOI: 10.5604/16652681.1171746] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
278 Britton L, Bridle K, Reiling J, Santrampurwala N, Wockner L, Ching H, Stuart K, Subramaniam VN, Jeffrey G, St Pierre T, House M, Gummer J, Trengove R, Olynyk J, Crawford D, Adams L. Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease. Hepatol Commun 2018;2:644-53. [PMID: 29881816 DOI: 10.1002/hep4.1190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
279 Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AKMK. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J Gastroenterol 2014;33:452-7. [DOI: 10.1007/s12664-014-0488-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
280 Ode KL, Frohnert BI, Nathan BM. Identification and treatment of metabolic complications in pediatric obesity. Rev Endocr Metab Disord 2009;10:167-88. [PMID: 19809879 DOI: 10.1007/s11154-009-9115-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
281 Rong B, Feng R, Liu C, Wu Q, Sun C. Reduced delivery of epididymal adipocyte‐derived exosomal resistin is essential for melatonin ameliorating hepatic steatosis in mice. J Pineal Res 2019;66:e12561. [DOI: 10.1111/jpi.12561] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
282 Rachakonda VP, Reeves VL, Aljammal J, Wills RC, Trybula JS, DeLany JP, Kienesberger PC, Kershaw EE. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity (Silver Spring). 2015;23:965-972. [PMID: 25865747 DOI: 10.1002/oby.20960] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
283 Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, Onori P, Alvaro D, Gaudio E. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology. 2012;56:2142-2153. [PMID: 22467277 DOI: 10.1002/hep.25742] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 11.3] [Reference Citation Analysis]
284 Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195-206. [PMID: 21497738 DOI: 10.1016/j.bpg.] [Reference Citation Analysis]
285 Barclay JL, Shostak A, Leliavski A, Tsang AH, Jöhren O, Müller-Fielitz H, Landgraf D, Naujokat N, van der Horst GT, Oster H. High-fat diet-induced hyperinsulinemia and tissue-specific insulin resistance in Cry-deficient mice. Am J Physiol Endocrinol Metab 2013;304:E1053-63. [PMID: 23531614 DOI: 10.1152/ajpendo.00512.2012] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 10.6] [Reference Citation Analysis]
286 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 25.5] [Reference Citation Analysis]